XPD Lys751Gln and Asp312Asn Polymorphisms and Gastric Cancer Susceptibility: A Meta-analysis of Case-control Studies

  • Yin, Qing-Hua (Department of Oncology, the First People's Hospital of Yueyang) ;
  • Liu, Chuan (Department of Oncology, Changhai Hospital, the Second Military Medical University) ;
  • Hu, Jian-Bing (Department of Oncology, the First People's Hospital of Yueyang) ;
  • Meng, Rong-Rong (Department of Oncology, Changhai Hospital, the Second Military Medical University) ;
  • Li, Lian (Yueyang Second People's Hospital) ;
  • Wang, Ya-Jie (Department of Oncology, Changhai Hospital, the Second Military Medical University)
  • Published : 2013.01.31


Background: Published data regarding the association between xeroderma pigmentosum group D (XPD) Lys751Gln and Asp312Asn polymorphisms and gastric cancer susceptibility havew been inconclusive. This meta-analysis was therefore performed toobtain a more precise estimation of any relationship. Materials and Methods: A comprehensive literature search was conducted to identify all case-control studies of Lys751Gln and Asp312Asn polymorphisms and susceptibility to gastric cancer. Summary odds ratios (ORs) and its 95% confidence intervals (95% CIs) were calculated using a random-effects model with the software STATA (version10.0). Results: A total of 12 case-control studies including 3,147 cases and 4,736 controls were included. Overall, no significant associations were found in some models (for Lys751Gln: Lys/Gln vs Lys/Lys: OR=1.144, 95% CI=0.851-1.541, Gln/Gln vs Lys/Lys: OR=1.215, 95% CI = 0.740-1.955, dominant model: OR=1.137, 95% CI=0.818-1.582; recessive model: OR=1.123, 95% CI=0.765-1.650; for Asp312Asn: Asp/Asn vs Asp/Asp: OR=1.180, 95% CI=0.646-2.154, dominant model: OR=1.380, 95% CI = 0.812-2.346), but significantly elevated susceptibility was found for Asp312Asn polymorphism in some models (Asn/Asn vs Asp/Asp: OR=2.045, 95% CI=1.254-3.335, recessive model: OR=1.805, 95% CI =1.219-2.672), for the additive model, the XPD Lys751Gln and Asp312Asn polymorphisms were not significantly associated with gastric cancer susceptibility. In stratified analyses, significantly elevated susceptibility was found for some models in the Chinese population. Conclusion: This meta-analysis suggested the XPD Asp312Asn polymorphism might be a potential biomarker of gastric cancer susceptibility in overall population, while both XPD Lys751Gln and Asp312Asn polymorphisms might be risk factors of gastric cancer susceptibility in Chinese.


  1. Zhang CZ, Chen ZP, Xu CQ(2009). Correlation of XPD gene with susceptibility to gastric cancer. Ai Zheng, 28, 1163-7.
  2. Jiao L, Hassan MM, Bondy ML, et al (2007). The XPD Asp312Asn and Lys751Gln polymorphisms, corresponding haplotype,and pancreatic cancer risk. Cancer Lett, 245, 61-8.
  3. Lee SG, Kim B, Choi J (2002). Genetic polymorphisms of XRCC1 and risk of gastric cancer. Cancer Lett, 187, 53-60.
  4. Long XD, Ma Y, Huang YZ (2010). Genetic polymorphisms in DNA repair genes XPC, XPD, and XRCC4, and susceptibility to Helicobacter pylori infection-related gastric antrum adenocarcinoma in Guangxi population, China. Mol Carcinog, 49, 611-8.
  5. Manuguerra M, Saletta F, Karagas MR (2006). XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: A HuGE review. Am J Epidemiol, 164, 297-302.
  6. Montecucco C, Rappuoli R (2001). Living dangerously: How Helicobacter pylori survives in the human stomach. Nat Rev, 2, 457-66.
  7. Palli D, Polidoro S, D’Errico M, et al (2010). Polymorphic DNA repair and metabolic genes: a multigenic study on gastric cancer. Mutagenesis, 25, 569-75.
  8. Ramos JM, Ruiz A, Colen R, et al (2004). DNA repair and breast carcinoma susceptibility in women. Cancer, 100, 1352-7.
  9. Ruzzo A, Canestrari E, Maltese P, et al (2007). Polymorphisms in genes involved in DNA repair and metabolism of xenobiotics in individual susceptibility to sporadic diffuse gastric cancer. Clin Chem Lab Med, 45, 822-8.
  10. Shen MR, Jones IM, Mohrenweiser H(1998). Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res, 58, 604-8.
  11. Shi Q, Wang LE, Bondy ML, et al (2004). Reduced DNA repair of benzo[a]pyrene diol epox-ideinduced adducts and common XPD polymorphisms in breast cancer patients. Carcinogenesis, 13, 1081-3.
  12. Spitz MR, Wu X, Wang Y, et al (2001). Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res, 61, 1354-7.
  13. Vodicka P, Kumar R, Stetina R, et al (2004). Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and singlestrand breaks in DNA. Carcinogenesis, 25, 757-63.
  14. Wood RD, Mitchell M, Sgouros J, et al (2001). Human DNA repair genes. Science, 291, 1284-9.
  15. Ye W, Kumar R, Bacova G, et al (2006). The XPD 751Gln allele is associated with an increased risk for esophageal adenocarcinoma: a population-based case-control study in Sweden. Carcinogenesis, 27, 1835-41.
  16. Yi Lou, Qing BS, Xiang MH (2006). Association of single nucleotide polymorphism in DNA repair gene XPD with gastric cancer in Han population from northeast region of China. Shijie Huaren Xiaohua Zazhi, 14, 3143-6.
  17. Yuan T, Deng S, Chen M, et al (2011). Association of DNA repair gene XRCC1 and XPD polymorphisms with genetic susceptibility to gastric cancer in a Chinese population. Cancer Epidemiol, 35, 170-4.
  18. Berwick M, Vineis P (2000). Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst, 92, 874-97.
  19. Canbay E, Agachan B, Gulluoglu M, et al (2010). Possible associations of APE1 polymorphism with susceptibility and HOGG1 polymorphism with prognosis in gastric cancer. Anticancer Res, 30, 1359-64.
  20. Chen Z, Zhang C, Xu C, et al (2011). Effects of selected genetic polymorphisms in xeroderma pigmentosum complementary group D on gastric cancer. Mol Biol Rep, 38, 1507-13.
  21. Cleaver JE (2000). Common pathways for ultraviolet skin carcinogenesis in the repair and replication defective groups of xeroderma pigmentosum. J Dermatol Sci, 23, 1-11.
  22. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
  23. Deng SL, Chen M, Chen W, et al (2010). Association of DNA repair gene polymorphisms with genetic susceptibility to gastric cancer. J Mol Diagn Ther, 6, 371-4.
  24. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
  25. Egger M, Davey Smith G, Schneider M, et al (1997). Bias in meta-analysis detected by a simple, graphical test. Br Med J, 315, 629-34.
  26. Engin AB, Karahalil B, Engin A, et al (2011). DNA repair enzyme polymorphisms and oxidative stress in a Turkish population with gastric carcinoma. Mol Biol Rep, 38, 5379-86.
  27. Hemminki K, Xu G, Angelini S, et al (2001). XPD exon 10 and 23 polymorphisms and DNA repair in human skin in situ. Carcinogenesis, 22, 1185-8.
  28. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
  29. Hirschhorn JN, Lohmueller K, Byrne E (2002). A comprehensive review of genetic association studies. Genet Med, 4, 45-61.
  30. Ahmedin J, Freddie B, Melissa M, et al (2011). Ward Global Cancer Statistics. CA Cancer J Clin, 61, 69-90.
  31. Au WW, Navasumrit P, Ruchirawat M, et al (2004). Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health, 107, 301-13.
  32. Benhamou S, Sarasin A (2002). ERCC2/XPD gene polymorphisms and cancer risk. Mutagenesis, 17, 463-9.
  33. Bertuccio P, Chatenoud L, Levi F, et al (2009). Recent patterns in gastric cancer: a global overview. Int J Cancer, 125, 666-73.
  34. Hoeijmakers JH (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411, 366-74.
  35. Huang WY, Chow WH, Rothman N, et al (2005). Selected DNA repair polymorphisms and gastric cancer in Poland. Carcinogenesis, 26, 1354-9.
  36. Hu JJ, Hall MC, Grossman L, et al (2004). Deficient nucleotide excision repair capacity enhances human prostate cancer risk. Cancer Res, 64, 1197-201.
  37. Ades AE, Lu G and Higgins JP (2005). The interpretation of random-effects meta-analysis in decision models. Med Decis Making, 25, 646-54.

Cited by

  1. XPD Lys751Gln and Asp312Asn Polymorphisms and Susceptibility to Skin Cancer: A Meta-Analysis of 17 Case-control Studies vol.15, pp.16, 2014,
  2. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: A meta-analysis vol.35, pp.3, 2014,
  3. The -786T > C polymorphism in the NOS3 gene is associated with increased cancer risk vol.35, pp.4, 2014,
  4. XPD Lys751Gln and Asp312Asn polymorphisms and hepatocellular carcinoma susceptibility: A meta-analysis of 11 case-control studies in an Asian population vol.9, pp.6, 2015,
  5. and the Risk of Prostate Cancer pp.1533-0338, 2017,
  6. Asp312Asn with Lung Cancer Risk: Evidence from 20,101 Subjects vol.18, pp.1, 2014,